Takayasu Arteritis Clinical Trial in China

NACompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

December 22, 2016

Primary Completion Date

May 22, 2022

Study Completion Date

November 22, 2022

Conditions
Takayasu Arteritis
Interventions
DRUG

Leflunomide(LEF)

"Leflunomide:~For LEF arm, 20mg per day, p.o. through the whole study. For placebo group, 20mg per day, p.o. from week 25 to week 52."

DRUG

Prednisone Acetate Tablets

Prednisone (5mg/tab): basic therapy, start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day.

DRUG

Placebos

2 tabs/d used in placebo arm for the first 24 weeks.

Trial Locations (6)

200032

Zhongshan hospital, Fudan University, Shanghai

Unknown

Beijing Anzhen Hospital, Beijing

The first affiliated hospital of Nanchang University, Nanchang

The First Hospital of China Medical University, Shenyang

Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Ürümqi

All Listed Sponsors
lead

Jiang lindi

OTHER

NCT02981979 - Takayasu Arteritis Clinical Trial in China | Biotech Hunter | Biotech Hunter